查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1413446

思覺失調症治療藥物市場：治療層級、劑量方法和配銷通路- 全球預測 2024-2030

Schizophrenia Therapeutics Market by Therapeutic Class (Second Generation, Third Generation), Administration (Injectable, Oral), Distribution Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年思覺失調症藥物市場規模為78.9億美元，2024年達80.8億美元，預計2030年將達110.6億美元，複合年成長率為4.94%。

全球思覺失調症藥物市場

主要市場統計
基準年[2023] 78.9億美元
預測年份 [2024] 80.8億美元
預測年份 [2030] 110.6億美元
複合年成長率（%） 4.94%
精神分裂症治療藥物市場-IMG1

FPNV定位矩陣

FPNV定位矩陣對於評估思覺失調症藥物市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對思覺失調症治療藥物市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴考察，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2-市場開拓：我們深入研究利潤豐厚的新興市場，並分析它們在成熟細分市場中的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-思覺失調症治療藥物市場的市場規模和預測是多少？

2-思覺失調症治療藥物市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些？

3-思覺失調症治療藥物市場的技術趨勢和法律規範是什麼？

4-思覺失調症治療藥物市場主要供應商的市場佔有率是多少？

5-進入思覺失調症藥物市場合適的型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球思覺失調症盛行率上升
      • 政府旨在提高人們對心理健康狀況認知的措施和宣傳活動
      • 正在進行研究以開發思覺失調症的有效治療方法
    • 抑制因素
      • 治療費用昂貴且不在保險範圍內
    • 機會
      • 人們對個人化醫療以提高思覺失調症患者的藥物療效越來越感興趣。
      • 思覺失調症的治療和治療方法進展
    • 任務
      • 與思覺失調症藥物相關的副作用
  • 市場區隔分析
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第6章依治療類別分類的思覺失調症治療藥物市場

  • 第二代
  • 第三代

第7章按管理分類的思覺失調症治療藥物市場

  • 可注射的
  • 口服

第8章思覺失調症治療藥物市場：按配銷通路

  • 醫院
  • 藥局
    • 離線
    • 線上的

第9章北美和南美思覺失調症治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區思覺失調症治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲的思覺失調症治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：按主要企業分類
  • 主要企業競爭情境分析

第13章競爭產品組合

  • 主要公司簡介
    • Acadia Pharmaceuticals Inc.
    • Alkermes Plc
    • Allergan Plc by AbbVie Inc.
    • Amneal Pharmaceuticals, LLC
    • Astellas Pharma Inc.
    • AstraZeneca plc
    • BioXcel Therapeutics, Inc.
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb and Company
    • Delpor, Inc.
    • Eli Lilly and Company
    • Gedeon Richter Plc
    • Johnson & Johnson Services, Inc.
    • Karuna Therapeutics Inc
    • Lundbeck A/S
    • Luye Pharma Group Ltd
    • Lyndra Therapeutics Inc
    • Meiji Holdings Co., Ltd.
    • Neurocrine Biosciences, Inc.
    • Otsuka America Pharmaceutical Inc.
    • Pfizer Inc.
    • Reviva Pharmaceuticals Holdings, Inc.
    • Sumitomo Dainippon Pharma Co., Ltd.
    • Takeda Pharmaceutical Company Limited
    • Vanda Pharmaceuticals Inc.
  • 主要產品系列

第14章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-8E22B61932E6

[192 Pages Report] The Schizophrenia Therapeutics Market size was estimated at USD 7.89 billion in 2023 and expected to reach USD 8.08 billion in 2024, at a CAGR 4.94% to reach USD 11.06 billion by 2030.

Global Schizophrenia Therapeutics Market

KEY MARKET STATISTICS
Base Year [2023] USD 7.89 billion
Estimated Year [2024] USD 8.08 billion
Forecast Year [2030] USD 11.06 billion
CAGR (%) 4.94%
Schizophrenia Therapeutics Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Schizophrenia Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Schizophrenia Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Schizophrenia Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Acadia Pharmaceuticals Inc., Alkermes Plc, Allergan Plc by AbbVie Inc., Amneal Pharmaceuticals, LLC, Astellas Pharma Inc., AstraZeneca plc, BioXcel Therapeutics, Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb and Company, Delpor, Inc., Eli Lilly and Company, Gedeon Richter Plc, Johnson & Johnson Services, Inc., Karuna Therapeutics Inc, Lundbeck A/S, Luye Pharma Group Ltd, Lyndra Therapeutics Inc, Meiji Holdings Co., Ltd., Neurocrine Biosciences, Inc., Otsuka America Pharmaceutical Inc., Pfizer Inc., Reviva Pharmaceuticals Holdings, Inc., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, and Vanda Pharmaceuticals Inc..

Market Segmentation & Coverage

This research report categorizes the Schizophrenia Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Therapeutic Class
    • Second Generation
    • Third Generation
  • Administration
    • Injectable
    • Oral
  • Distribution Channel
    • Hospital
    • Pharmacies
      • Offline
      • Online
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Schizophrenia Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Schizophrenia Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Schizophrenia Therapeutics Market?

4. What is the market share of the leading vendors in the Schizophrenia Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Schizophrenia Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Schizophrenia Therapeutics Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of schizophrenia disorder among individuals worldwide
      • 5.1.1.2. Government initiatives and campaigns to raise awareness regarding mental health conditions
      • 5.1.1.3. Ongoing research for the development of efficient drugs for schizophrenia
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment and lack of insurance coverage
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing focus on personalized medicine for improving drug efficacy in patients with schizophrenia disorder
      • 5.1.3.2. Advancements in schizophrenia treatment and therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with the medications prescribed for schizophrenia
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Schizophrenia Therapeutics Market, by Therapeutic Class

  • 6.1. Introduction
  • 6.2. Second Generation
  • 6.3. Third Generation

7. Schizophrenia Therapeutics Market, by Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral

8. Schizophrenia Therapeutics Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital
  • 8.3. Pharmacies
    • 8.4.1. Offline
    • 8.4.2. Online

9. Americas Schizophrenia Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Schizophrenia Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Schizophrenia Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Acadia Pharmaceuticals Inc.
    • 13.1.2. Alkermes Plc
    • 13.1.3. Allergan Plc by AbbVie Inc.
    • 13.1.4. Amneal Pharmaceuticals, LLC
    • 13.1.5. Astellas Pharma Inc.
    • 13.1.6. AstraZeneca plc
    • 13.1.7. BioXcel Therapeutics, Inc.
    • 13.1.8. Boehringer Ingelheim International GmbH
    • 13.1.9. Bristol-Myers Squibb and Company
    • 13.1.10. Delpor, Inc.
    • 13.1.11. Eli Lilly and Company
    • 13.1.12. Gedeon Richter Plc
    • 13.1.13. Johnson & Johnson Services, Inc.
    • 13.1.14. Karuna Therapeutics Inc
    • 13.1.15. Lundbeck A/S
    • 13.1.16. Luye Pharma Group Ltd
    • 13.1.17. Lyndra Therapeutics Inc
    • 13.1.18. Meiji Holdings Co., Ltd.
    • 13.1.19. Neurocrine Biosciences, Inc.
    • 13.1.20. Otsuka America Pharmaceutical Inc.
    • 13.1.21. Pfizer Inc.
    • 13.1.22. Reviva Pharmaceuticals Holdings, Inc.
    • 13.1.23. Sumitomo Dainippon Pharma Co., Ltd.
    • 13.1.24. Takeda Pharmaceutical Company Limited
    • 13.1.25. Vanda Pharmaceuticals Inc.
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. SCHIZOPHRENIA THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. SCHIZOPHRENIA THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
  • FIGURE 8. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 10. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. SCHIZOPHRENIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. SCHIZOPHRENIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. SCHIZOPHRENIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 6. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 9. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 12. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 15. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 56. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 60. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 64. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 68. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 72. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 76. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 80. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 84. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 88. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 92. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 101. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 105. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 109. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 113. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 117. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 121. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 125. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 129. NETHERLANDS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. NETHERLANDS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. NETHERLANDS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 133. NIGERIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. NIGERIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. NIGERIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 137. NORWAY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. NORWAY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. NORWAY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 141. POLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. POLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. POLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 145. QATAR SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. QATAR SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. QATAR SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 149. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 153. SAUDI ARABIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. SAUDI ARABIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. SAUDI ARABIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 157. SOUTH AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. SOUTH AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. SOUTH AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 161. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 165. SWEDEN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 166. SWEDEN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. SWEDEN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 169. SWITZERLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. SWITZERLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. SWITZERLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 173. TURKEY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. TURKEY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. TURKEY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 177. UNITED ARAB EMIRATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. UNITED ARAB EMIRATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. UNITED ARAB EMIRATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 185. SCHIZOPHRENIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 186. SCHIZOPHRENIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 187. SCHIZOPHRENIA THERAPEUTICS MARKET LICENSE & PRICING